Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) | Zendy

Simona Di Giambenedetto | Zendy; Massimiliano Fabbiani | Zendy; Eugenia Quirós-Roldán | Zendy; Alessandra Latini | Zendy; Gabriella d’Ettorre | Zendy; Andrea Antinori | Zendy; Antonella Castagna | Zendy; Giancarlo Orofino | Zendy; Daniela Francisci | Zendy; Pierangelo Chinello | Zendy; Giordano Madeddu | Zendy; Pierfrancesco Grima | Zendy; Stefano Rusconi | Zendy; Massimo Di Pietro | Zendy; Annalisa Mondi | Zendy; Nicoletta Ciccarelli | Zendy; Alberto Borghetti | Zendy; Emanuele Focà | Zendy; Manuela Colafigli | Zendy; Andrea De Luca | Zendy; Roberto Cauda | Zendy

Open Access

Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M)

Author(s) -

Simona Di Giambenedetto,

Massimiliano Fabbiani,

Eugenia Quirós-Roldán,

Alessandra Latini,

Gabriella d’Ettorre,

Andrea Antinori,

Antonella Castagna,

Giancarlo Orofino,

Daniela Francisci,

Pierangelo Chinello,

Giordano Madeddu,

Pierfrancesco Grima,

Stefano Rusconi,

Massimo Di Pietro,

Annalisa Mondi,

Nicoletta Ciccarelli,

Alberto Borghetti,

Emanuele Focà,

Manuela Colafigli,

Andrea De Luca,

Roberto Cauda

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw557

Subject(s) - atazanavir , ritonavir , lamivudine , medicine , regimen , pharmacology , virology , gastroenterology , viral load , human immunodeficiency virus (hiv) , virus , antiretroviral therapy , hepatitis b virus

Combination ART (cART)-related toxicities and costs have prompted the need for treatment simplification. The ATLAS-M trial explored 48 week non-inferior efficacy of simplification to atazanavir/ritonavir + lamivudine versus maintaining three-drug atazanavir/ritonavir-based cART in virologically suppressed patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research